1 milligram for 550 EURO !! IST-9 mAb reacts both with sections from frozen and paraformaldehyde fixed tissues. IST-9 reacts with the C’-C’ loop of ED-A preventing ED-A binding with integrins alpha5-beta1, alpha4-beta1 and alpha9-beta1. IST-9 inhibits fibroblasts differentiation into myo-fibroblasts and TGF-beta activation, thus inhibiting fibrosis (see under the Antibodies section). More recently it has […]
Archive for Uncategorized
SIRIUS-BIOTECH ACQUIRED A NOVEL ANTIBODY SPECIFIC FOR NEO-FORMING BLOOD VESSELS
Sirius-biotech has acquired from the National Cancer Institute of Genoa the patent for the mAb C6. The mAb C6 recognizes a novel fibronectin epitope unmasked by the insertion of the extra-domain B. This antibody, specifically reacting with neoforming blood vessels, represents a new tool for the targeting of tissues undergoing neoangiogenesis and for the study of novel fibronectin […]
Sirius-biotech to offer mAb BC-1 specific for the angiogenesis
Sirius-biotech to offer the mAb BC-1 specific for the angiogenesis, associated B-FN as well as a large panel of antibodies for different epitopes of human fibronectin
Uteroglobin procedure published
SIRIUS-biotech personnel collaborated in the publication of the uteroglobin procedure for the generation of polyvalent polyspecific fusion proteins (patent pending). For further references, please consult: Ref. Ventura E. et al. “Use of uteroglobin for the engineering of polyvalent, polyspecific fusion proteins”, 2009, J Biol Chem, 284:26646-26654.
